
    
      This is a randomized, double-blind, placebo-controlled, parallel-group, phase II trial set up
      to investigate the efficacy, safety and physiological effects of prucalopride 1 mg
      administered o.d. for 4 weeks to female patients with chronic idiopathic constipation. The
      primary objective of this trial was to assess the effect of prucalopride 1 mg on whole gut
      transit (measured as changes from baseline in total number of markers).
    
  